Education
About Us
Working with TipRanks
Follow Us
Matthew B. Klein Insider Profile
4 Followers
Matthew B. Klein, CEO, Director at PTC Therapeutics, holds 337.77K shares in PTC Therapeutics (Ticker: PTCT), holds 50.52K shares in ClearPoint Neuro (Ticker: CLPT).
Matthew B. Klein PTC Therapeutics (PTCT)CEO, Director
PTC Therapeutics (PTCT)
CEO, Director
Ranked #89,683 out of 103,606 Corporate Insiders
Profitable Transactions
4 out of 12 Profitable Transactions
Average Return
-18.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Matthew B. Klein holds in companies
Most Profitable Insider Trade
The most profitable trade made by Matthew B. Klein
Matthew B. Klein's Trading History
PTC Therapeutics
Aug 05, 2025
CEO, Director
Uninformative Buy
―
$22.08M
ClearPoint Neuro
May 19, 2025
Director
Uninformative Buy
278.01K
$1.38M
List of latest transactions for each holding click on a transaction to see Matthew B. Klein's performance on stock
You May Also Like
Matthew B. Klein insider profile FAQ
What is the percentage of profitable transactions made by Matthew B. Klein?
The percentage of profitable transactions made by Matthew B. Klein is 33%.
What is the average return per transaction made by Matthew B. Klein?
The average return per transaction made by Matthew B. Klein is -18.60%.
What stocks does Matthew B. Klein hold?
Matthew B. Klein holds: PTCT, CLPT stocks.
What was Matthew B. Klein’s latest transaction?
Matthew B. Klein latest transaction was an Uninformative Buy of ―.
What was Matthew B. Klein's most profitable transaction?
Matthew B. Klein’s most profitable transaction was an Informative Sell of PTCT stock on April 20, 2023. The return on the trade was 52.90%.
What is Matthew B. Klein's role in PTC Therapeutics?
Matthew B. Klein's role in PTC Therapeutics is CEO, Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.